A5016383093- Systemic Lupus Erythematosus Research
- Systemic Sclerosis and Related Diseases
- Liver Diseases and Immunity
- Monoclonal and Polyclonal Antibodies Research
- Inflammatory Myopathies and Dermatomyositis
- Bariatric Surgery and Outcomes
- Gestational Diabetes Research and Management
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- PI3K/AKT/mTOR signaling in cancer
- Hepatitis C virus research
- Diabetes Management and Education
- Gastric Cancer Management and Outcomes
- Blood disorders and treatments
- Multiple and Secondary Primary Cancers
- Esophageal Cancer Research and Treatment
- Cancer, Lipids, and Metabolism
- Cytokine Signaling Pathways and Interactions
- Global Health Care Issues
- Erythropoietin and Anemia Treatment
- Helicobacter pylori-related gastroenterology studies
- Inflammatory Biomarkers in Disease Prognosis
Medical University of Lublin
2014-2024
Antiphospholipid antibodies in uterine malignancies 1037 INTROduCTION Thrombosis is a common complication observed patients with malignancies. 1-3Several factors responsible for the development of thrombosis have been identified.Interactions between cancer cells, coagulation mechanisms, and immune system may play an essential role initiating thrombotic processes accompanying tumors. 4-9Women reproductive tract malignancies, including (UMs), are at high risk thromboembolic complications also...
Every year, over 600,000 new cases of esophageal cancer are registered worldwide. Treatment depends on the stage disease. In early stages, surgical treatment is basis (T1–T2 lesion < 3 cm, N0M0), while in more advanced preceded by radiochemotherapy or only used. case generalized disease, main treatments used systemic chemotherapy, immunotherapy and palliative teleradiotherapy brachytherapy. Brachytherapy can be at virtually any both as a radical treatment. This paper presents...
<h3>Background</h3> Patients with uterine malignancies (UM) are at a higher risk of venous thromboembolism (VTE) than the general population. The malignancy itself, treatment modalities including medication, surgery and also increased levels leukocytes, platelets, tissue factor-positive microvesicles contribute to developing VTE. <h3>Objectives</h3> Several authors have shown that antiphospholipid antibodies (aPLs) can be detected in peripheral blood patients (pts) malignancies. However,...
<h3>Background</h3> The relationships between the occurrence of antibodies used in clinical practice for diagnosis and monitoring disease activity systemic lupus erythematosus (SLE) criteria SLICC classification system are a matter discussion. <h3>Objectives</h3> aim study was to investigate whether there any presence characteristic SLE detected by multiparametric assay. <h3>Methods</h3> involved 81 (72-female 9-male) consecutive patients treated Department Rheumatology Connective Tissue...
<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease in which the uncontrolled activation of immune system leads to overproduction autoantibodies (Ab) with different mechanisms action. Coexistence anti-phospholipid antibodies (aPL) significantly increases risk thromboembolic complications and worsens clinical course prognosis SLE. Objectives: The aim study was determine relationship between presence non-criteria aPLs SLE patients criteria...
<h3>Background</h3> Antiphospholipid syndrome (APS) could be diagnosed as primary (PAPS) or secondary (SAPS - accompanying other diseases, mainly found in patients with systemic lupus erythematosus -SLE) <h3>Objectives</h3> The aim of our study was to determine if pts PAPS and SAPS had different clinical serological status. <h3>Methods</h3> involved 80 (59-f 21-m) APS (pts) 24 56 following SLE. In the whole group mean age was: 39.3± 12.7 years (range 18-71), duration disease 8.8 ± 8.3 0-37)....
Background: The exact pathogenesis of systemic lupus erythematosus (SLE) is poorly understood. It an autoimmune disease that leads to a chronic inflammatory process involving numerous tissues and organs (skin, kidneys, joints, central nervous system, cardiovascular, respiratory, digestive hematopoietic systems). However, despite the advancement SLE molecular biology wide availability tests diagnostic tools, knowledge about factors predicting clinical activity as well related changes in...